Pacemaker Implantation — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

A cardiac pacemaker is a small implantable battery-powered electronic device that monitors the heart's electrical rhythm and delivers precisely timed electrical impulses through implanted leads to maintain an adequate and appropriately responsive heart rate when the heart's own electrical conduction system fails to do so reliably. First successfully implanted in a human by Rune Elmqvist and Ake Senning in Stockholm in 1958, pacemakers have undergone continuous technological refinement over six decades and are now one of the most commonly implanted cardiac devices worldwide, with over one million implantations performed globally each year.

Modern pacemakers are classified by their lead configuration and function. Single-chamber pacemakers pace the right ventricle (VVI) or right atrium (AAI) using one lead. Dual-chamber pacemakers pace both the right atrium and right ventricle using two leads (DDD) — maintaining natural atrioventricular (AV) synchrony and superior haemodynamic performance compared with single-chamber devices. Cardiac resynchronisation therapy pacemakers (CRT-P) use a third lead placed in a coronary sinus branch to simultaneously pace the left ventricle, resynchronising the two ventricles in heart failure patients with left bundle branch block. Leadless pacemakers — miniaturised devices implanted directly in the right ventricle via a catheter through the femoral vein — eliminate the pocket and lead complications of conventional systems and are approved for single-chamber ventricular pacing.

All modern pacemakers are programmable via telemetry from an external programmer, allowing non-invasive adjustment of pacing rate, sensitivity, output, and rate-responsive algorithms. Remote monitoring via bedside transmitters sends device data to the electrophysiology clinic at scheduled intervals or in response to arrhythmia detection, enabling early identification of lead or battery issues without clinic attendance.

Permanent pacemaker implantation is indicated for symptomatic or clinically significant bradycardia from intrinsic disease of the sinoatrial node or the atrioventricular conduction system, confirmed by 12-lead ECG, ambulatory cardiac monitoring (24-hour Holter, 7-day monitor, implantable loop recorder), or electrophysiological study.

Sinoatrial node disease (sick sinus syndrome): Sick sinus syndrome encompasses sinus bradycardia with symptoms (fatigue, presyncope, syncope, exertional dyspnoea), sinus arrest (pauses over 3 seconds causing syncope), sinoatrial block, chronotropic incompetence (failure of the heart rate to rise appropriately with exercise — a critical functional limitation), and tachy-brady syndrome (alternating rapid atrial arrhythmias and slow sinoatrial node rates after termination).

Atrioventricular conduction disease: - Second-degree Mobitz Type II AV block: Unpredictable intermittent failure of P-wave conduction to the ventricle — carries high risk of progression to complete heart block and sudden cardiac death even when asymptomatic; pacemaker is a Class I indication regardless of symptoms - Third-degree (complete) AV block: Complete dissociation of atrial and ventricular electrical activity with subsidiary escape rhythm — always a Class I indication for permanent pacing - Symptomatic Mobitz Type I (Wenckebach): Progressive PR prolongation with eventual dropped beat — pacemaker indicated when symptomatic with documented correlation - Acquired left bundle branch block with syncope and abnormal electrophysiological study

Post-procedural heart block: High-degree AV block following transcatheter aortic valve replacement (TAVI), open cardiac surgery, or catheter ablation — permanent pacemaker if block persists beyond 5-7 days.

Cardiac resynchronisation therapy (CRT-P): Indicated for patients with heart failure, reduced left ventricular ejection fraction (under 35%), and left bundle branch block with QRS duration over 130-150 ms who remain symptomatic despite optimal medical therapy — reduces hospitalisation by 36% and mortality by 24% in appropriate candidates (CARE-HF, COMPANION trials).

Contraindications: Reversible causes of bradycardia (hypothyroidism, hyperkalaemia, medication toxicity, hypothermia, vagal episodes) must be excluded before permanent pacing. Active systemic infection, life expectancy under 1 year from non-cardiac causes, and patient refusal after detailed informed consent counselling are contraindications.

Pacemaker implantation is performed in a cardiac catheterisation laboratory or electrophysiology suite equipped with fluoroscopic X-ray guidance. The procedure takes 1-2 hours and is performed under local anaesthesia with conscious sedation in the vast majority of patients.

Pre-operative preparation: Patients fast for 6 hours before the procedure. IV access is established in the contralateral arm. A 12-lead ECG and chest radiograph confirm the indication. Blood tests include full blood count, coagulation screen, and metabolic panel. Anticoagulant medications are managed per the electrophysiology team's protocol — warfarin is often continued if the INR is therapeutic, as the risk of periprocedural haematoma is lower than the risk of thromboembolism from interruption.

Skin preparation and anaesthesia: The left (or right, depending on patient factors) infraclavicular area is surgically prepared with chlorhexidine solution and draped. Local anaesthetic (lidocaine 1% with adrenaline) is infiltrated into the skin, subcutaneous tissue, and deep pectoral fascia. Conscious sedation with midazolam and fentanyl provides anxiolysis and analgesia while maintaining patient cooperation for instruction following.

Venous access: The subclavian or cephalic vein is accessed — the cephalic vein cut-down approach avoids the pneumothorax risk of subclavian puncture. For subclavian access, the needle is directed under fluoroscopic guidance along the inferior border of the clavicle. One or two guidewires are introduced and exchanged for appropriately sized introducer sheaths.

Lead placement: Under continuous fluoroscopic guidance, the ventricular lead is advanced through the subclavian vein, through the right atrium, across the tricuspid valve, and positioned at the right ventricular apex or (preferably) the His-bundle or left bundle branch pacing site for more physiological conduction. The atrial lead (for dual-chamber pacing) is positioned in the right atrial appendage. Lead pacing threshold, sensing amplitude, and impedance are measured to confirm satisfactory electrical contact with the myocardium. CRT pacemakers additionally require the left ventricular lead to be advanced through the coronary sinus into a lateral or posterolateral cardiac vein, the most technically challenging aspect of the procedure.

Pulse generator pocket: A subcutaneous pocket is created in the infraclavicular region using a combination of sharp and blunt dissection deep to the subcutaneous fat and superficial to the pectoralis major fascia — the prepectoral pocket. The leads are connected to the pulse generator, which is placed in the pocket with appropriate slack in the leads to allow arm movement. The pocket is closed in layers with absorbable sutures.

Post-implantation testing: The device is programmed to the appropriate pacing settings, sensitivity, and rate response parameters. A chest radiograph confirms lead positions and excludes pneumothorax. The paced ECG is recorded to confirm ventricular capture.

Permanent pacemaker implantation is highly effective in eliminating the symptoms and risks of bradyarrhythmia, improving quality of life, functional capacity, and in high-degree AV block, preventing sudden cardiac death.

Symptom relief: Bradycardia-related symptoms — fatigue, presyncope, syncope, dyspnoea on exertion — resolve in over 95% of patients after appropriate pacemaker implantation. Rate-responsive pacing (DDDR mode) restores the ability to increase heart rate with physical activity, significantly improving exercise tolerance and quality of life in patients with chronotropic incompetence.

Survival: For patients with complete AV block, pacemaker implantation normalises survival to match age-matched controls without conduction disease. Without pacing, complete AV block carries a 1-year mortality of over 50% from bradyarrhythmic sudden cardiac death.

Device longevity: Battery longevity varies by pacing rate, energy required per pulse, and percentage pacing dependency: 8-12 years for most dual-chamber pacemakers. Generator replacement at end-of-life is a brief procedure (30-45 minutes) retaining the existing leads in almost all cases, with the same low complication rate as the initial implant.

CRT outcomes: For appropriate heart failure patients (LVEF under 35%, LBBB, QRS over 150 ms), CRT-P reduces hospitalisation by 36% and mortality by 24% compared with optimal medical therapy alone (CARE-HF, COMPANION trials). CRT additionally reverses ventricular remodelling — increasing LVEF by 5-10% in responders — in approximately 60-70% of treated patients.

Permanent pacemaker implantation is a safe procedure at experienced centres with an overall major complication rate of 3-5%. Understanding the specific risks helps patients make informed decisions.

Pneumothorax: Occurs in 1-2% with subclavian venous access from inadvertent pleural puncture. Most are small and detected on the post-procedure chest radiograph; the majority resolve without intervention. Larger pneumothorax (over 20%) requires chest drain insertion for 24-48 hours.

Lead dislodgement: Lead migration from the intended endocardial position occurs in 1-3% within the first 6 weeks, before the lead has fibrotically incorporated into the myocardium. May present as pacing failure or new pacing threshold elevation on device interrogation. Requires lead repositioning in a second procedure.

Pocket haematoma: Post-operative collection of blood in the generator pocket occurs in 2-5%, more frequently in patients on anticoagulation or antiplatelet agents. Most resolve with conservative management (external compression dressing, ice packs, anticoagulation dose adjustment). Evacuation under anaesthesia is required for expanding or infected haematomas.

Device infection: Superficial wound infection occurs in under 1%. Deep pocket or lead infection — colonisation of the device by Staphylococcus aureus or epidermidis — occurs in 0.5-1% and typically requires complete device extraction and antibiotic therapy, followed by re-implantation at a new site 1-4 weeks later. Device infection management at specialist heart rhythm centres using percutaneous lead extraction is highly successful.

Cardiac perforation: Right ventricular or atrial perforation from a lead tip is rare (under 0.5%) and may cause haemopericardium, tamponade, or diaphragmatic stimulation. Managed with pericardiocentesis if tamponade occurs.

Pacemaker syndrome: In single-chamber VVI pacemakers pacing the ventricle without AV synchrony, retrograde conduction from ventricle to atrium can cause atrial contraction against a closed tricuspid valve, causing presyncope, pulsations in the neck, and breathlessness. Managed by upgrading to a dual-chamber device.

MRI access: Older pacemakers are MRI-incompatible. All new pacemakers implanted at experienced centres are MR-conditional (tested at 1.5T and 3T under specified conditions), allowing access to brain, spine, and most body MRI scans with appropriate device programming.

Recovery from pacemaker implantation is rapid, and most patients are discharged the morning after the procedure.

Night of procedure: Patients are admitted to a cardiac monitoring ward. The paced ECG, vital signs, and oxygen saturation are monitored overnight. The chest radiograph is reviewed for lead position and pneumothorax. The wound is inspected for haematoma. Oral diet resumes on the evening of the procedure.

Discharge (Day 1): Patients are discharged with a wound care leaflet, pacemaker identification card, and detailed instructions for arm restriction. An appointment for the 6-week device check is arranged. Antibiotic wound care is prescribed.

Arm restriction (weeks 1-6): The ipsilateral arm must not be raised above shoulder level, used for heavy lifting, or involved in vigorous overhead activity for 4-6 weeks. This restriction allows fibrous tissue to anchor the pacemaker leads securely to the endocardium before movement stress is applied. Violation of these restrictions is the primary cause of early lead dislodgement. The arm can be used normally for keyboard work, eating, and light daily activities.

Wound care: The incision is kept dry for 5-7 days — showering is permitted if the wound is covered with a waterproof dressing; bathing and swimming are avoided until the wound is fully healed. Sutures are either absorbable or removed at 10-14 days. Any redness, increasing warmth, swelling, discharge, or fever must prompt immediate review to exclude wound infection.

Device interrogation: The pacemaker is checked at 6 weeks post-implantation using a bedside programmer to assess lead thresholds, impedance, sensing, battery voltage, and pacing data. The programming is optimised if needed. Subsequent checks are performed at 3 months and then every 6-12 months, with remote monitoring transmissions supplementing clinic visits at most centres.

Activity and driving: Most patients may drive standard vehicles 1 week after implantation, once the wound is comfortable and arm function is adequate. Heavy goods vehicle (HGV) driving requires physician assessment. Contact sports and activities near strong electromagnetic fields (industrial welders, arc welders, high-voltage power lines) are discussed at the 6-week review.